Public Company Watch

Insights on Securities, Governance, M&A, Shareholder Activism, and Securities Litigation and Enforcement

FPO: Jasper Therapeutics to Merge with Amplitude Healthcare Acquisition Corporation to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation

By Jason M. Rednour on September 26, 2018

posted in Antitrust

FPO:

Palo Alto – Paul Hastings LLP, a leading global law firm, announced today that the firm served as legal advisor to Jasper Therapeutics, Inc. (Jasper Therapeutics) in its agreement to merge with Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company (SPAC).

The merger will result in Jasper Therapeutics becoming a publicly listed company. The combined company will be named Jasper Therapeutics Inc. and is expected to remain listed on Nasdaq and trade under the new ticker symbol “JSPR.” Amplitude Healthcare Acquisition Corporation trades under the symbol “AMHC.”

As LexBlog’s Kevin O’Keefe explains:

“Blogging is much more than ‘message sending.’ You listen to the conversation that’s already taking place among leaders and the media covering your niche area of expertise. Only after listening can you engage in the discussion by referencing the discussion in your blog posts and commenting at other blogs.”

These links explain what listening means and why it’s an important component of your blogging efforts:

These tools can help you listen to your audience and identify authors, articles, and other important conversations in your industry:

testing article link

testing category link

Direct to Your Inbox

Subscribe and Receive Real-Time Updates from the Public Company Watch!